Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: A pooled analysis of three trials

导出原文传递

翻译打印收藏纠错

作者： Modest,D.P. ^[1] ; Brodowicz,T. ^[2] ; Stintzing,S. ^[3] ; Jung,A. ^[4] ; Neumann,J. ^[5] ; Laubender,R.P. ^[6] ; Ocvirk,J. ; Kurteva,G. ; Papai,Z. ; Knittelfelder,R. ; Kirchner,T. ; Heinemann,V. ; Zielinski,C.C.

作者单位： Central European Cooperative Oncology Group, Medical University of Vienna, Vienna, Austria, AEK ^[1] Central European Cooperative Oncology Group, Medical University of Vienna, Vienna, Austria ^[2] Department of Medicine III, University Hospital Grosshadern, Germany ^[3] Institutes of Pathology, University of Munich, Munich, Germany ^[4] Institutes of Medical Informatics, Biometry and Epidemiology, University of Munich, Munich, Germany ^[5] Central European Cooperative Oncology Group, Medical University of Vienna, Vienna, Austria, SBALO ^[6]

关键词 Anti-epidermal growth factor receptor Cetuximab Codon 12 KRAS mutation Metastatic colorectal cancer

发布时间 2013-11-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交